Home - Chinese Journal of Cancer Research

2021 Impact Factor of CJCR: 4.026
Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

National Health Commission of the People’s Republic of China

Cancer burden and trends in China: A review and comparison with Japan and South Korea

Cancer is the leading cause of death worldwide. Distinct geographic disparities exist in cancer burden across the world. China, Japan, and South Korea are all located in East Asia. As neighboring countries, Japan and South Korea share similar genetic backgrounds and similar culture with China. Also, in terms of cancer burden, these three countries are all facing a heavy burden of upper digestive tract cancers. This article provides an overview of cancer burden and trends in China by comparing with Japan and South Korea. Comparison among these three countries for the cancer burden and trends could be useful to track the effectiveness of national screening programs and to identify modifiable risk factors. The results can serve as a scientific reference for cancer control policy planning.

Cancer incidence and mortality in China, 2014

In 2017, National Central Cancer Registry of China (NCCRC) updated nationwide cancer statistics using population-based cancer registry data in 2014 collected from all available cancer registries. There are 449 cancer registries submitted cancer registry data in 2014, among which 339 registries’ data met the criteria of quality control and were included in analysis. These cancer registries covered 288,243,347 population, accounting for about 21.07% of the national population in 2014. Numbers of nationwide new cancer cases and deaths were estimated using calculated incidence and mortality rates and corresponding national population stratified by area, sex, age group and cancer type. The world Segi’s population was applied for age-standardized rates. Heavy cancer burden and its disparities between area, sex and age group pose a major challenge to public health in China. Nationwide cancer registry plays a crucial role in cancer prevention and control.

Cancer incidence in Beijing, 2014

To analyze cancer incidence data in Beijing in 2014 and temporal trends for selected common cancers during 2005 and 2014. A total of 144 secondary and tertiary hospitals reported newly diagnosed cancer cases to Beijing Cancer Registry, which covers 13 million residents in Beijing. The cancer incidence rate was calculated in strata by cancer type, sex, age group and area. The population composition of China in 1982 and Segi’s population structure were used to calculate age-standardized rates. Extensive procedures were used to assure the quality of the data. A total of 45,300 new cancer cases were diagnosed in Beijing in 2014. The incidence rate was 341.92/100,000 (343.50/100,000 in males, 340.33/100,000 in females). Cancer remains an important public health problem. Actions should be taken to diminish total cancer incidence in Beijing.

‹ ›

Vol 33, No 3 (June 2021)

NHCPRC Guidelines

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 309-334 HTML

National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 335-342 HTML

Original Article

Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer

Dan Lyu, Binliang Liu, Bo Lan, Xiaoying Sun, Lixi Li, Jingtong Zhai, Haili Qian, Fei Ma

Pages: 343-352 HTML

Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China

Hanxiao Chen, Xiangjuan Ma, Jie Liu, Yu Yang, Yong Fang, Liping Wang, Jian Fang, Jun Zhao, Minglei Zhuo

Pages: 353-364 HTML

Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer

Quan Jiang, Chenyu Tian, Hao Wu, Lingqiang Min, Hao Chen, Lingli Chen, Fenglin Liu, Yihong Sun

Pages: 365-382 HTML

Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Changlong Li, Zhen Guan, Yi Zhao, Tingting Sun, Zhongwu Li, Weihu Wang, Zhexuan Li, Lin Wang, Aiwen Wu

Pages: 383-394 HTML

Development and validation of a predictive model for endocervical curettage in patients referred for colposcopy: A multicenter retrospective diagnostic study in China

Peng Xue, Bingrui Wei, Samuel Seery, Qing Li, Zichen Ye, Yu Jiang, Youlin Qiao

Pages: 395-405 HTML

Protocol

Laparoscopic vs. open lower mediastinal lymphadenectomy for Siewert type II/III adenocarcinoma of esophagogastric junction: An exploratory, observational, prospective, IDEAL stage 2b cohort study (CLASS-10 study)

Shuangxi Li, Xiangji Ying, Fei Shan, Yongning Jia, Zhemin Li, Kan Xue, Rulin Miao, Yinkui Wang, Zhaode Bu, Xiangqian Su, Ziyu Li, Jiafu Ji

Pages: 406-414 HTML

Perspective

Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation

Limin Zou, Yueli Qi, Ling Tang, Yu Du, Meiyi Xiang, Xiaoming Chen, Jun Ma, Zhimin Yang

Pages: 415-421 HTML

Editorial

Subpopulation cooperation renders drug resistance of hepatobiliary tumor organoids

Kuo Qi, Rong Liu

Pages: 422-424 HTML

NHCPRC Guidelines

National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 309-334 HTML

National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 335-342 HTML

National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 131-150 HTML

National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 151-175 HTML

National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 176-206 HTML

National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 207-237 HTML

National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 238-255 HTML

National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 256-269 HTML

National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 270-288 HTML

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

National Health Commission of the People’s Republic of China

Pages: 415-445 HTML

Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 707-737 HTML

Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 578-585 HTML

Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 557-577 HTML

Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 223-258 HTML

Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 259-277 HTML

Chinese guidelines for diagnosis and treatment of pancreatic cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 278-294 HTML

Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 295-305 HTML

Chinese guidelines for diagnosis and treatment of primary lung cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 1-28 HTML

Chinese guidelines for diagnosis and treatment of renal cell carcinoma 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 29-48 HTML

Chinese guidelines for diagnosis and treatment of urothelial carcinoma of bladder 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 49-66 HTML

Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version)

National Health Commission of the People’s Republic of China

Pages: 67-83 HTML

CSCO Guidelines

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology

Pages: 289-301 HTML

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan

Pages: 302-307 HTML

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

2021 Impact Factor of CJCR: 4.026Journal Citation Reports®, Clarivate Analytics

National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)

Cancer burden and trends in China: A review and comparison with Japan and South Korea

Cancer incidence and mortality in China, 2014

Cancer incidence in Beijing, 2014

About cjcr

Advertising

Contact us

NHCPRC Guidelines

Original Article

Protocol

Perspective

Editorial

NHCPRC Guidelines

CSCO Guidelines

Virtual Special Issues

Beijing Cancer Hospital

China Anti-cancer Association

Chronic Diseases and Translational Medicine

2018 CGCC

2021 Impact Factor of CJCR: 4.026
Journal Citation Reports®, Clarivate Analytics